The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.

19 patients with primary open angle glaucoma (POAG) refractory to topical medical therapy were operated in late 2020 and a novel interposition supraciliary device implanted.

These patients reached 6 months follow-up and the original study had to be interrupted.

This observational study prolonges follow-up to 36 months

Inclusion Criteria:

• All patients who were implanted in this center with the novel supraciliary interposition device under the scope of clinical trial NCT03736655

Exclusion Criteria:

• if cannot assist to all future follow-up visits

All patients who were implanted in this center with the novel supraciliary interposition device under the scope of clinical trial NCT03736655